Literature DB >> 23162624

Expression of UDP-glucuronosyltransferase 1A, nuclear factor erythroid-E2-related factor 2 and Kelch-like ECH-associated protein 1 in colonic mucosa, adenoma and adenocarcinoma tissue.

Min Wang1, Ying-Ying Qi, Shuo Chen, DE-Feng Sun, Shuai Wang, Jian Chen, Yan-Qing Li, Wei Han, Xiao-Yun Yang.   

Abstract

We investigated the expression of UDP-glucuronosyltransferase 1A (UGT1A), nuclear factor erythroid-E2-related factor 2 (Nrf2) and Kelch-like ECH-associated protein 1 (Keap1) in normal colonic mucosa, adenoma tissue and adenocarcinoma tissue, to analyze the correlation between their expression and the clinicopathological features of adenocarcinoma and their roles in colonic carcinogenesis. Using immunohistochemical analysis, we investigated the expression of UGT1A, Nrf2 and Keap1 in normal colonic mucosa (n=24), adenoma tissue (n=30) and adenocarcinoma tissue (n=77). We found that the positive rate of UGT1A was 83.3% in normal colonic mucosa, 80.0% in adenoma tissue and significantly lower, 53.2%, in adenocarcinoma tissue (normal colonic vs. adenoma tissue, P=0.071; normal colonic vs. adenocarcinoma tissue, P=0.023; adenoma vs. adenocarcinoma tissue, P=0.019). The expression levels of Nrf2 were high in adenoma and adenocarcinoma tissues, with positive rates of 70.0 and 87.0%, respectively, but were significantly lower in normal colonic tissue, with a positive rate of 41.7% (normal colonic vs. adenoma tissue, P=0.000; normal colonic vs. adenocarcinoma tissue, P=0.000; adenoma vs. adenocarcinoma tissue, P=0.000). The positive rate of Keap1 was 54.2% in normal mucosa, 70.0% in adenoma tissue and 61.0% in adenocarcinoma tissue (normal colonic mucosa vs. adenoma tissue, P=0.200; normal colonic vs. adenocarcinoma tissue, P=0.040; adenoma vs. adenocarcinoma, P=0.002). In addition, there was no correlation between the expression of Nrf2/Keap1 in adenoma and adenocarcinoma tissues (r=0.067, P=0.723; r=0.042, P=0.715, respectively). The results suggest that decreased expression of UGT1A and the dysregulation of the Nrf2/Keap1 system may be related to colonic carcinogenesis.

Entities:  

Year:  2012        PMID: 23162624      PMCID: PMC3499601          DOI: 10.3892/ol.2012.850

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  22 in total

1.  Nuclear oncoprotein prothymosin alpha is a partner of Keap1: implications for expression of oxidative stress-protecting genes.

Authors:  Ruben N Karapetian; Alexandra G Evstafieva; Irina S Abaeva; Nina V Chichkova; Grigoriy S Filonov; Yuri P Rubtsov; Elena A Sukhacheva; Sergey V Melnikov; Ulrich Schneider; Erich E Wanker; Andrey B Vartapetian
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

2.  Evaluation of Nrf2 and IGF-1 expression in benign, premalignant and malignant gastric lesions.

Authors:  Hong-Bo Wang; Cheng-Jun Zhou; Su-zhen Song; Peng Chen; Wei-hua Xu; Bin Liu; Kong-xi Zhu; Wei-hua Yu; Hong-lei Wu; Hong-juan Wang; Sen Lin; Jian-qiang Guo; Cheng-yong Qin
Journal:  Pathol Res Pract       Date:  2011-03-01       Impact factor: 3.250

3.  Genetic ablation of Nrf2 enhances susceptibility to cigarette smoke-induced emphysema in mice.

Authors:  Tirumalai Rangasamy; Chung Y Cho; Rajesh K Thimmulappa; Lijie Zhen; Sorachai S Srisuma; Thomas W Kensler; Masayuki Yamamoto; Irina Petrache; Rubin M Tuder; Shyam Biswal
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

4.  An important function of Nrf2 in combating oxidative stress: detoxification of acetaminophen.

Authors:  K Chan; X D Han; Y W Kan
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-03       Impact factor: 11.205

5.  UDP-glucuronosyltransferases 1A expression in human urinary bladder and colon cancer by immunohistochemistry.

Authors:  Laura Giuliani; Marco Ciotti; Antonella Stoppacciaro; Anna Pasquini; Ida Silvestri; Anna De Matteis; Luigi Frati; Anna-Maria Aglianò
Journal:  Oncol Rep       Date:  2005-02       Impact factor: 3.906

6.  Oncogenic NRF2 mutations in squamous cell carcinomas of oesophagus and skin.

Authors:  Yoo Ri Kim; Ji Eun Oh; Min Sung Kim; Mi Ran Kang; Sang Wook Park; Ji Youn Han; Hyeon Seok Eom; Nam Jin Yoo; Sug Hyung Lee
Journal:  J Pathol       Date:  2010-03       Impact factor: 7.996

7.  Physical and functional interaction of sequestosome 1 with Keap1 regulates the Keap1-Nrf2 cell defense pathway.

Authors:  Ian M Copple; Adam Lister; Akua D Obeng; Neil R Kitteringham; Rosalind E Jenkins; Robert Layfield; Brian J Foster; Christopher E Goldring; B Kevin Park
Journal:  J Biol Chem       Date:  2010-04-08       Impact factor: 5.157

8.  Multidrug-resistant protein-3 gene regulation by the transcription factor Nrf2 in human bronchial epithelial and non-small-cell lung carcinoma.

Authors:  Christopher M Mahaffey; Hongqiao Zhang; Alessandra Rinna; William Holland; Philip C Mack; Henry Jay Forman
Journal:  Free Radic Biol Med       Date:  2009-04-05       Impact factor: 7.376

Review 9.  Genetic polymorphisms of UDP-glucuronosyltransferases and their functional significance.

Authors:  John O Miners; Ross A McKinnon; Peter I Mackenzie
Journal:  Toxicology       Date:  2002-12-27       Impact factor: 4.221

10.  Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy.

Authors:  Adam Lister; Taoufik Nedjadi; Neil R Kitteringham; Fiona Campbell; Eithne Costello; Bryony Lloyd; Ian M Copple; Samantha Williams; Andrew Owen; John P Neoptolemos; Chris E Goldring; B Kevin Park
Journal:  Mol Cancer       Date:  2011-04-13       Impact factor: 27.401

View more
  2 in total

Review 1.  Research progress on chemopreventive effects of phytochemicals on colorectal cancer and their mechanisms.

Authors:  Teng-Fei Yin; Min Wang; Ying Qing; Ying-Min Lin; Dong Wu
Journal:  World J Gastroenterol       Date:  2016-08-21       Impact factor: 5.742

Review 2.  Species differences in drug glucuronidation: Humanized UDP-glucuronosyltransferase 1 mice and their application for predicting drug glucuronidation and drug-induced toxicity in humans.

Authors:  Ryoichi Fujiwara; Emiko Yoda; Robert H Tukey
Journal:  Drug Metab Pharmacokinet       Date:  2017-10-07       Impact factor: 3.614

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.